RITZ-5: Randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of Pulmonary edema: A prospective, multicenter, double-blind, placebo-controlled study

The objective of this study was to evaluate the addition of intravenous (IV) tezosentan to standard therapy for patients with pulmonary edema. Tezosentan is an IV nonselective endothelin (ET)-1 antagonist that yields favorable hemodynamic effects in patients with acute congestive heart failure (CHF)...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2003-01, Vol.41 (2), p.204-210
Main Authors: KALUSKI, Edo, KOBRIN, Isaac, VERED, Zvi, COTTER, Gad, ZIMLICHMAN, Reuven, MARMOR, Alon, KRAKOV, Oscar, MILO, Olga, FREY, Aline, KAPLAN, Shoshana, KRAKOVER, Rikardo, CASPI, Avi
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cardiovascular system
Double-Blind Method
Echocardiography
Endothelin Receptor Antagonists
Heart Failure - complications
Heart Failure - diagnostic imaging
Humans
Injections, Intravenous
Medical sciences
Miscellaneous
Pharmacology. Drug treatments
Prospective Studies
Pulmonary Edema - drug therapy
Pulmonary Edema - etiology
Pyridines - administration & dosage
Pyridines - therapeutic use
Tetrazoles - administration & dosage
Tetrazoles - therapeutic use
Treatment Outcome
Vasodilator Agents - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to evaluate the addition of intravenous (IV) tezosentan to standard therapy for patients with pulmonary edema. Tezosentan is an IV nonselective endothelin (ET)-1 antagonist that yields favorable hemodynamic effects in patients with acute congestive heart failure (CHF). Pulmonary edema was defined as acute CHF leading to respiratory failure, as evidenced by an oxygen saturation (SO(2))
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(02)02708-0